Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1693
This examiner grants 32% of resolved cases
David H Cho is an examiner in Tech Center 1600 and Art Unit 1693, with 47 resolved cases. The allowance rate is 31.9%, which is the baseline for success in this queue. However, the interview lift is 67.0%, indicating that interviews are an exceptionally powerful tool for increasing the probability of allowance over the 31.9% baseline. This suggests that direct communication is the most effective strategy for success with this examiner.
The median days to allowance is 1248, reflecting the typical timeline for the 47 resolved cases. This 1248-day metric is an important factor for practitioners in Art Unit 1693. Given the 67.0% interview lift, direct engagement is highly recommended to overcome the 31.9% allowance rate. The examiner's history suggests that while the initial path is difficult, interviews provide a very strong route to a positive outcome. Attorneys can use these metrics from Tech Center 1600 to manage their strategy.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18294123 | METHOD FOR REDUCING ENDOTOXIN LEVELS IN NUCLEIC ACID PURIFICATION | Non-Final OA | MERCK PATENT GMBH |
| 18702922 | TREATMENT OF VIRUSES WITH ANTIVIRAL NUCLEOSIDES | Non-Final OA | EMORY UNIVERSITY |
| 17996452 | CYCLODEXTRIN BASED ANTI-MICROBIAL THERAPY | Non-Final OA | University of Southern California |
| 18554922 | NOVEL USE | Final Rejection | DSM IP ASSETS B.V. |
| 18546264 | METHODS FOR REDUCING PATHOGENIC E COLI BY SELECTIVE FEED ADDITIVE INTERVENTION | Non-Final OA | DSM IP Assets B.V. |
| 17906560 | METHODS AND COMPOSITIONS FOR TREATMENT OF CORONAVIRUS INFECTION | Non-Final OA | Battelle Memorial Institute |
| 18088628 | COMPOUND, SOLID CARRIER INCLUDING THE SAME AND METHOD FOR PREPARING NUCLEIC ACID | Final Rejection | Industrial Technology Research Institute |
| 18883218 | COMPOSITION FOR IMPROVING FATIGUE, EXERCISE PERFORMANCE, OR ENDURANCE COMPRISING GALLOCATECHIN GALLATE AND ISOQUERCITRIN | Non-Final OA | AMOREPACIFIC CORPORATION |
| 17799320 | USE OF COMPOUNDS THAT ARE ABLE TO CROSS-LINK THE EXTRACELLULAR MATRIX FOR PREVENTING OR INHIBITING THE MIGRATION OF CANCER CELLS | Final Rejection | CAMBRIDGE ENTERPRISE LIMITED |
| 18613537 | 3'-OH RNA-CONTAINING OLIGONUCLEOTIDE DEPROTECTION | Non-Final OA | ALNYLAM PHARMACEUTICALS, INC. |
| 18705643 | 3D PRINTING SUPPORT MATERIAL AND METHOD FOR MANUFACTURING SAME | Non-Final OA | OSAKA UNIVERSITY |
| 18720268 | COMPOSITIONS FOR PREVENTING OR FOR REDUCING RISK OF DEVELOPING SECONDARY INFECTIOUS DISEASES | Non-Final OA | MEIJI CO., LTD. |
| 18548833 | TRIAZOLYL-METHYL SUBSTITUTED ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | Final Rejection | Idorsia Pharmaceuticals Ltd |
| 18549452 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | Non-Final OA | NeuroDerm, Ltd. |
| 18007407 | NOVEL THERAPEUTIC USES OF COMPOUNDS FOR ENHANCING MITOCHONDRIAL FUNCTION AND TREATING MITOCHONDRIAL DISEASES | Final Rejection | THE CHILDREN'S HOSPITAL OF PHILADELPHIA |
| 18740787 | CHEMICAL SYNTHESIS OF CYTIDINE-5'-MONOPHOSPHO-N-GLYCYL-SIALIC ACID | Non-Final OA | 89bio, Inc. |
| 18012729 | CONJUGATE OF A SINGLE DOMAIN ANTIBODY, A SAPONIN AND AN EFFECTOR MOLECULE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, THERAPEUTIC USE OF SAID PHARMACEUTICAL COMPOSITION | Final Rejection | SAPREME TECHNOLOGIES B.V. |
| 18168394 | ENCAPSULATED PRECURSORS OF NICOTINAMIDE ADENINE DINUCLEOTIDE AND METHODS OF MAKING THE SAME | Final Rejection | Nulixir Inc. |
| 17614099 | Chitosan and Applications Thereof | Final Rejection | KIOMED PHARMA |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy